UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • An in vivo genetic reversio...
    Le Guen, Tangui, PhD; Touzot, Fabien, MD, PhD; André-Schmutz, Isabelle, PhD; Lagresle-Peyrou, Chantal, PhD; France, Benoit, MSc; Kermasson, Laetitia; Lambert, Nathalie; Picard, Capucine, MD, PhD; Nitschke, Patrick, PhD; Carpentier, Wassila, PhD; Bole-Feysot, Christine, PhD; Lim, Annick, PhD; Cavazzana, Marina, MD, PhD; Callebaut, Isabelle, PhD; Soulier, Jean, MD, PhD; Jabado, Nada, MD, PhD; Fischer, Alain, MD, PhD; de Villartay, Jean-Pierre, PhD; Revy, Patrick, PhD

    Journal of allergy and clinical immunology, 12/2015, Letnik: 136, Številka: 6
    Journal Article

    Background Myb-Like, SWIRM, and MPN domains 1 (MYSM1) is a metalloprotease that deubiquitinates the K119-monoubiquitinated form of histone 2A (H2A), a chromatin marker associated with gene transcription silencing. Likewise, it has been reported that murine Mysm1 participates in transcription derepression of genes, among which are transcription factors involved in hematopoietic stem cell homeostasis, hematopoiesis, and lymphocyte differentiation. However, whether MYSM1 has a similar function in human subjects remains unclear. Here we describe a patient presenting with a complete lack of B lymphocytes, T-cell lymphopenia, defective hematopoiesis, and developmental abnormalities. Objectives We sought to characterize the underlying genetic cause of this syndrome. Methods We performed genome-wide homozygosity mapping, followed by whole-exome sequencing. Results Genetic analysis revealed that this novel disorder is caused by a homozygous MYSM1 missense mutation affecting the catalytic site within the deubiquitinase JAB1/MPN/Mov34 (JAMM)/MPN domain. Remarkably, during the course of our study, the patient recovered a normal immunohematologic phenotype. Genetic analysis indicated that this improvement originated from a spontaneous genetic reversion of the MYSM1 mutation in a hematopoietic stem cell. Conclusions We here define a novel human immunodeficiency and provide evidence that MYSM1 is essential for proper immunohematopoietic development in human subjects. In addition, we describe one of the few examples of spontaneous in vivo genetic cure of a human immunodeficiency.